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Stem cells are undifferentiated and pluripotent cells that can differentiate into specialized
cells with a more specific function. Stem cell therapies become preferred methods for the
treatment of multiple diseases. Oral and maxillofacial defect is one kind of the diseases
that could be most possibly cured by stem cell therapies. Here we discussed oral
diseases, oral adult stem cells, iPS cells, and the progresses/challenges/perspectives
of application of stem cells for oral disease treatment.
Keywords: adult stem cells, iPS cells, oral and maxillofacial defect, stem cell therapy, clinical trial, precisely
controlled differentiation
INTRODUCTION
Stem cells are undifferentiated and pluripotent cells that can produce more new stem cells (self-
renewal) and differentiate into specialized cells with a more specific function such as skin cells,
bone cells, and blood cells (Weissman, 2000). The major sources of stem cells include embryonic
stem cells, adult stem cells, perinatal stem cells, and induced pluripotent stem cells (iPS cells). Stem
cell research and clinical application has been dramatically advanced since the great invention of
the iPS cell technology pioneered by Shinya Yamanaka in 2006 (Takahashi and Yamanaka, 2006).
Stem cells have been reported for the therapy of multiple diseases such as leukemia, lymphoma,
brain and spinal cord injury, heart failure, hearing loss, blindness and vision impairment, teeth
missing, and other degenerative diseases. Oral and maxillofacial defect (Figure 1) is one kind of the
diseases that could be most probably cured by stem cell therapy.
ORAL AND MAXILLOFACIAL DEFECTS
The oral and maxillofacial areas consist of many different types of tissues. It differs one from
another and affects not only the functions of breathing, chewing, speech and smell, etc., but also
esthetics and have much influence on the patients psychologically especially after accident injuries
or tumor section (Mao and Prockop, 2012). The defects occurred in oral area can be divided into
four main groups: dental hard tissue defect, pulpal disease, periodontal diseases, and maxillofacial
defects (Table 1).
Dental Defects
Dental Hard Tissue Defects
Dental caries is one of the most common reasons to cause dental hard tissue defects. It is a
multifactorial disease caused by the demineralization of tooth enamel surface by oral bacteria, thus
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FIGURE 1 | Schematic of common oral and maxillofacial defects.
weakening its structure (Soares et al., 2016). Non-carious lesions
as a result of normal, abnormal, or pathological wear could cause
abfraction, abrasion, and erosion or chemical degradation of
dental tissues (Mjor, 2001). Dental traumatic injuries are caused
by an external impact on a tooth and its surrounding tissues
(Feliciano and de Franca Caldas, 2006). Up to now, direct filling
is the main treatment method of dental hard tissues defects, in
which either amalgam or composite resins would be used to
restore the dental defects (Sequeira-Byron et al., 2015). However,
there still exists problems like removing some healthy tissues to
gain retention for amalgam (Ozcan et al., 2010) or shrinkage, easy
to wear and aging, etc., for composite resins (Tantbirojn et al.,
2011).
Pulpal Diseases
Pulpitis refers to the inflammatory state of the dental pulp,
clinically described as reversible or irreversible and histologically
described as acute, chronic, or hyperplastic (Hargreaves et al.,
2016). It often happens when there has been dental caries or
trauma (Trowbridge, 1981). Root canal therapy has hitherto been
applied to deal with pulpitis regularly. In this procedure, the
inflammatory tissues are extracted, mechanical preparation of the
root canals are carried out and then obturation would be done
with filling materials to stop the bacteria from stepping into the
root canal systems as well as the periodontal parts (Hargreaves
et al., 2016). However, clearing up all the pulpal tissues leave
the teeth insensitive, losing nutrients, and properties change of
enamel and dentin.
Periodontal Diseases
Periodontitis is the most common periodontal disease, which is
a term referring to the inflammation of periodontium. Periapical
periodontitis usually arises from inflammatory expansion from
root canal systems. And more often, periodontitis origins from
stimuli of oral bacteria. It would cause lesions of gingiva,
attachment, alveolar bone and eventually the tooth loss (Caton
et al., 2011). The methods to treat the periodontitis are
subgingival scaling and root planning. However, the tissue loss
can’t be reversal, and these methods would only stabilize the
situations.
Maxillofacial Defects
Maxillofacial tissues are important to individuals. People
might have much trouble living confidently when suffering
maxillofacial defects, usually caused by congenital anomalies,
infections, trauma, and tumor section. Effective reconstruction
or regeneration of the damaged part would be beneficial to
patients both physiologically and psychologically (Mao and
Prockop, 2012; Mertens et al., 2016). Flap transplants combined
with dental implants or obturators are currently the main
therapy methods to rehabilitate the defected tissues, however,
the functions and esthetics still remain to be improved (Mertens
et al., 2016; Okay et al., 2016; Wijbenga et al., 2016).
STEM CELLS SUITABLE FOR TREATMENT
OF ORAL AND MAXILLOFACIAL DEFECTS
Stem cells are defined as the cells that can proliferate to
achieve self-renewal and differentiate into multiple cell lineages
(Weissman, 2000). There are four main types of stem cells:
(1) embryonic stem (ES) cells from embryos; (2) adult stem
cells from adult tissues; (3) perinatal stem cells existing in
amniotic fluid; and (4) induced pluripotent stem cells (iPS
cells) transformed from regular adult cells using genetic
reprogramming. ES cells are the stem cells with the best
pluripotency but ethical, legal, and medical considerations have
hindered the development in clinical applications (Murray et al.,
2007), especially when embryo has to be destructed to collect
enough stem cells. Amniotic fluid stem cells need to be more
studied to understand their potential. Therefore, we focus on
the adult stem cells and iPS cells which could be used for the
treatment of oral and maxillofacial defects.
Oral-Derived Adult Stem Cells
Adult stem cells, also called somatic stem cells or postnatal stem
cells (Tatullo et al., 2015), are harvested directly from adults.
They are multipotent cells, only differentiating into limited types
of cells or mesenchymal origin (Caplan, 1991). Dental tissues
including bone marrow, dental pulp, dental follicle, periodontal
ligament, apical papilla, and gingiva are good sources of adult
stem cells. These cells commonly express specific molecular
markers and can be isolated (Table 2). Recently, oral cavity have
been paid more and more attention to gaining somatic stem cells
as it’s more flexible for the surgeons to harvest the tissues without
undue trauma to the patients (Mao and Prockop, 2012).
There are different types of somatic stem cells in oral and
maxillofacial compartments or “stem cell niches” (Figure 2).
They are stem cells of the apical papilla (SCAP), inflammatory
periapical progenitor cells (iPAPCs), dental follicle stem cells
(DFSCs), dental pulp stem cells (DPSCs), periodontal ligament
stem cells (PDLSCs), bone marrow stem cells (BMSCs), tooth
germ progenitor cells (TGPCs), salivary gland stem cells (SGSCs),
stem cells from human exfoliated deciduous teeth (SHED),
oral epithelial stem cells (OESCs), gingival-derived mesenchymal
stem cells (GMSCs), and periosteal derived stem cells (PSCs;
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TABLE 1 | Oral and maxillofacial defects and their therapy.
Dental hard tissue defects Dental pulpal diseases Periodontal diseases Maxillofacial defects
Features Dental hard tissues turn dark,
soft, or tissue loss caused by
dental plaque, chemical erosion,
trauma or abrasion
Dental pulpal inflammation or
degradation caused by invasion
of bacteria or stimuli of physical
or chemical factors
Gingiva, periodontal ligament,
alveolar bone, or cementum
inflammation or loss caused by
dental plaque, debris, or calculus
Maxillary or mandible bone, teeth
in it, or soft tissue loss caused by
tumor section, trauma, or
congenital factors
Routine
treatment
Amalgam or composite filling,
occlusal veneer, or crown
Root canal therapy Scaling and root planning; graft
materials to compensate for the
bone loss, barrier membranes for
guided tissue regeneration, with
bioactive molecules combined
Skin graft, flap reconstruction, or
obturator rehabilitation
Stem cell
therapy
No available reports Dental stem cells, growth
factors, and scaffolds have been
respectively or conjunctively
utilized to regenerate dental pulp
and cementum-like, bone-like, or
periodontal-like tissues could be
generated in dental pulpal canals
Dental stem cells have been
utilized in periodontal
regeneration both in animal
models and in clinical trials and
proved to be safe
Mesenchymal and
adipose-derived stem cells with
scaffolds like
calcium/phosphate-based
bioactive ceramics and polymer
based scaffolds, and bioactive
factors like BMP, platelet-derived
growth factors, and TGF-β, have
been applied to defected sites
Perspectives The assembly of amelogenin and
other enamel matrix proteins, the
proteolytic activity, and
crystallization need to be in
precise synergy with each other
in order to produce the dental
enamel
The clarification of the dental
genetic modulating mechanisms,
identification of good positional
or cell lineage–specific markers
of the dental pulp, the screening
of appropriate scaffolds and the
search for trophic factors
maintaining are basic research
objectives of dental
bioengineering
Identification and isolation of the
appropriate groups of stem cells
and mimic a proper condition for
their proliferation and
differentiation are the first step.
The delivering systems and
scaffolds to support and facilitate
their regenerative capacity are
also of vital importance. Finally, in
order for these cells to be used
in humans, strict protocols
according to the principles of
Good Clinical Practice (GCP) and
Good Manufacturing Practice
(GMP) will be required
Suitable population of stem cells
should be identified and
harvested to fulfill the
physiological role of the native
tissue. Growth factors should be
studied to support cellular
differentiation and reproduction,
and the role the microvasculature
plays in tissue regeneration.
Adverse events, such as
infection, should be studied
more deeply. Scaffolds should be
investigated from the views of
both clinicians and engineers
References Uskokovic, 2015 Hargreaves et al., 2016;
Mari-Beffa et al., 2017
Menicanin et al., 2015; Wang
et al., 2015; Baba and Yamada,
2016; Chen et al., 2016;
Panduwawala et al., 2016.
Krebsbach et al., 1997; Ueda
et al., 2005; Rajan et al., 2014;
Smith et al., 2015; Mele et al.,
2016
Liao et al., 2011; Egusa et al., 2012). Most adult stem cells we
could get in oral and maxillofacial areas are mesenchymal stem
cells (MSCs). Pre-clinical studies of their utilization in treatment
of several diseases have been extensively conducted in animal
models (Table 2).
Oral-Derived Induced Pluripotent Stem
(iPS) Cells
iPS cells are the pluripotent stem cells induced through
reprogramming somatic cells genetically by introducing defined
factors (Takahashi and Yamanaka, 2006). IPS technology is
considered to be one of the most significant discovery and may
make great contribution to the treatment of diseases. It brings
hope to solve the ethical problems encountered by the application
of human ES cells and limited material source for both ES cells
and adult stem cells. Subsequently, a lot of studies have reported
that defined transcription factors can directly induce one cell
type converting to another without going through a pluripotent
state, further promoting iPS cell technology (Zhou et al., 2008;
Szabo et al., 2010; Vierbuchen et al., 2010; Huang et al., 2011;
Kim E. Y. et al., 2016). During 10 year studies of iPS cells,
extensive studies are focused on the multiple sides of iPS cells
including method optimization, clinical application exploration,
and the mechanisms of iPS cell reprogramming (Karagiannis
and Eto, 2016). Most notably, iPS cell technology have made
significant progresses in regenerative medicine that is to replace
damaged organ part by establishing a normal functional cells,
tissues or the whole organ (Mason and Dunnill, 2008).
In the field of dentistry, for the regeneration of periodontal
tissues, alveolar bone, and tooth are urgently needed. As
iPS cell technology is considered to have great potentials,
researchers are interested in the dental-tissue-derived iPS cells
and the application of iPS cells in dental tissue regeneration.
It was shown that three kinds of human dental stem cells:
DPSCs, SHED, and SCAP, could be induced to generate iPS
cells by introducing 3–4 factors with higher efficiency than
human fibroblasts (Figure 3; Yan et al., 2010). Mesenchymal
stromal cells derived from human third molars also can be
reprogramed into iPS cells with high efficiency in a similar
strategy (Oda et al., 2010). However, cells such as dental pulp
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TABLE 2 | Features and applications of oral-derived adult stem cells.
Resources Markers Terminal cells Applications (References)
BMSCs Bone marrow STRO-1+
CD73+
CD90+
CD14−
CD34 −
CD45−
Osteoblasts, Chondrocytes,
Adipocytes, Cardiomyocytes,
Myoblasts, and Neural cells
Treatment of periodontitis in human; Bone
Regeneration Using Bone Marrow Stromal Cells;
enhancement of new bone formation in
immunocompromised mouse and rabbit models of
distraction osteogenesis (DO); treatment of spinal cord injury
in rat (Krebsbach et al., 1997; Menabde et al., 2009; Baba
and Yamada, 2016; Ma et al., 2016; Okuda et al., 2017)
DPSCs Dental pulp CD105+
CD13+
CD73+
CD34−
CD45−
Odontoblast, Osteoblast,
Chondrocyte, Cardiomyocytes,
Neuron cells, Adipocyte, Corneal
epithelial cell, Melanoma cell, Insulin
secreting Beta cells
Restore mandible bone defects in human; bone
regeneration in a rat critical-size calvarial defect model
(d’Aquino et al., 2009a; Giuliani et al., 2013; Potdar and
Jethmalani, 2015; Chamieh et al., 2016)
DFSCs Dental follicle CD44+
CD90+
CD150+
STRO-1+
Adipocytes, Osteocytes, Neural cells,
Cementocytes, Periodonatal tissue
Enhancement of bone regeneration on titanium
implants surfaces in human; cardiomyocyte differentiation
and regeneration in vitro (Kemoun et al., 2007; Lucaciu et al.,
2015; Sung et al., 2016; Lima et al., 2017)
Gingival Gingival CD146+
CD105+
CD34−
Osteoblasts, Adipocytes, Periodontal regeneration in miniature-pigs; tendon
regeneration in mouse model (Zhang et al., 2009;
Moshaverinia et al., 2014; Fawzy El-Sayed et al., 2015;
Fawzy El-Sayed and Dörfer, 2016)
PDLSCs Periodontal
ligament
STRO-1+
CD146+
Adipocytes, Cementoblasts,
Osteoblasts, Neural crest-like cells
Treatment of periodontal defects in human; tooth
replacement; cementum regeneration in vitro; tendon
regeneration in mouse model (Feng et al., 2010; Gault et al.,
2010; Moshaverinia et al., 2014; Chen et al., 2016; Cho et al.,
2016)
SCAP Apical papilla STRO-1+
CD146+
CD34−
CD45−
Odontoblasts, Osteoblasts Generation of cell-based three dimensional (3D) nerve tissue
in vitro (Otsu et al., 2014; Kim B. C. et al., 2016)
SHEDs Human exfoliated
deciduous tooth
STRO-1+
CD44+
CD146+
Adipocytes, Odontoblasts, Neural
cells, Osteoblasts
Generate a functional dental pulp when injected into
full-length root canals in vitro; treatment of Alzheimer’s
disease (Rosa et al., 2013; Otsu et al., 2014)
FIGURE 2 | Schematic of potential sources of adult stem cells in the oral environment. Cell types include tooth germ progenitor cells (TGPCs); dental follicle
stem cells (DFSCs); salivary gland stem cells (SGSCs); stem cells of the apical papilla (SCAP); dental pulp stem cells (DPSCs); inflamed periapical progenitor cells
(iPAPCs); stem cells from human exfoliated deciduous teeth (SHED); periodontal ligament stem cells (PDLSCs); bone marrow stem cells (BMSCs); oral epithelial stem
cells (OESCs); gingival-derived mesenchymal stem cells (GMSCs); and periosteal stem cells (PSCs).
and apical papilla are not convenient to isolate from patients
for the donor tissues cannot regenerate. Human deciduous
teeth might be discarded after exfoliation, so human deciduous
tooth dental pulp cells (HDDPCs) are considered as better iPS
cell source (Tamaoki et al., 2010). Using gingival fibroblasts
as iPS cell source is another wise choice. Gingiva can be
easily acquired from patients with no need of tooth or pulp
extraction surgery and have relatively high reprogramming
efficiency (Egusa et al., 2010; Wada et al., 2011; Arakaki et al.,
2013).
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FIGURE 3 | Routine application of oral derived adult stem cells and iPS cells. The figure shows dental resources of adult stem cells which, as well as fibroblast
cells, are also resources of iPS cells. Adult stem cells directly differentiate into specialized cells or are induced into iPS cells. iPS cells induced from adult stem cells or
fibroblast cells could be driven to differentiate into specialized cells. Specialized cells form final tissues and organs. DP, dental pulp; OMFs, Oral mucosa fibroblasts;
MSLCs, Mesenchymal stem-like cells; PDL, periodontal ligament.
APPLICATIONS OF SOMATIC STEM CELLS
IN ORAL AND MAXILLOFACIAL REPAIR
AND REGENERATION
Stem cell therapy has become a promising alternative in dentistry
and maxillofacial rehabilitation since it could provide better
physiological structure and functions (Rada et al., 2002; d’Aquino
et al., 2009b; Caton et al., 2011; Tatullo et al., 2015). Regenerative
dentistry aims to regenerate the damaged dental tissues and
to regain the tooth morphology and functions (Figure 3 and
Table 2). There are total 44 registered clinical trials correlated
with oral stem cell or oral disease (Table 3). The stem cells used
in the clinical trials include MSCs (N = 14, included five trials
of BM-MSCs), PDLSCs (N = 4), OESCs (N = 12), DPSCs (N
= 5), adipose derived stem cells (ADSCs; N = 6), SHED (N =
1), nasal stem cells (N = 1), and HSCs (N = 1). As outlined
in Table 4, there are seven trials proposed to treat periodontal
disease with autologous MSCs, ADSCs, PDLSCs, or allogeneic
DPSCs. Three of them have reported results as shown in Table 4
and Supplementary Table 1. There are four clinical trials with
reported results from total 14 trials for bone disease therapy with
bone marrow stromal cells, nasal stem cells, allogeneic MSCs,
and ADSCs. There are 11 trials for eye diseases with autologous
OESC sheets but none has reported results yet. The other diseases
with clinical trials include dental pulp diseases (N = 3, with
autologous SHED or DPSCs), dental diseases correlated with
tooth extraction (N = 2, treated with OESCs or DPSCs), graft
vs. host diseases with oral complications (N = 2, treated by HSCs
or MSCs), facial diseases (N = 2, with autologous ADSCs), and
Xerostomia/Sjögren’s Syndrome (N = 2, with autologous ADSCs
or allogeneic MSCs). Among them, three trials have reported
results. The clinical trials with reported results will be discussed
below.
Somatic Stem Cells with Scaffolds in Oral
and Maxillofacial Repair and Regeneration
Scaffolds Used in Oral and Maxillofacial Repair and
Regeneration
Accurately designed scaffolds may improve the oral and
maxillofacial regeneration (Lee et al., 2010; Mitsiadis et al.,
2012; Hayashi et al., 2015). Scaffolds in oral and maxillofacial
regeneration are three-dimensional (3D) biomaterials mimicking
Frontiers in Physiology | www.frontiersin.org 5 April 2017 | Volume 8 | Article 197
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extracellular matrix facilitating cell-scaffold interactions, cell
survival, proliferation, and differentiation. Thus, the scaffolds are
mainly made of degradable and low toxic materials (Horst et al.,
2012). There are four main types of scaffolds including natural
polymers, synthetic polymers, calcium phosphate-based ceramic
scaffolds, and composite scaffolds. More details of chemical
structure, features and applications of scaffolds could be found
in the literature (Mele et al., 2016). Scaffold materials are often
applied together with stem cells and bioactive factors such as
bone morphogenetic proteins (BMPs; Luu et al., 2007), vascular
endothelial growth factor (VEGF; Schipani et al., 2009), platelet-
derived growth factor (PDGF; Fiedler et al., 2004; Phipps et al.,
2012), and SDF-1 (Kitaori et al., 2009). More details about growth
factors used for craniofacial and bone regeneration could be
found in the recent review (Mele et al., 2016).
The stem cells responded differently to various types of
scaffolds (Motamedian et al., 2016). Eluted zinc released
from zinc-modified titanium which is frequently applied in
dental and maxillofacial implantation could stimulate osteoblast
differentiation of DPSCs (Yusa et al., 2016a,b). Mangano et al.
found that laser sintered titanium surface enhanced DPSCs to
quickly differentiate into osteoblasts and endotheliocytes and
then produce bone tissues along the implant surfaces. Eventually,
a complete osteointegration was obtained (Mangano et al., 2010).
After hooking into the biocoral scaffolds, DPSCs moved into the
cavities and differentiated into osteoblasts, forming an engineer
biocomplexs (Mangano et al., 2011). Giuliani et al. used the
Micro-CT as an effective tool to observe the proliferation rate
of different cells on the PLGA scaffolds (Giuliani et al., 2014).
The porous PLGA microscaffolds have been proved to enhance
the adhesion of DPSCs, meanwhile maintaining the viability,
stemness, and plasticity of the cultured dental pulp mesenchymal
stem cells (Bhuptani and Patravale, 2016). And the scaffold
morphology was also confirmed to influence the long-term
kinetics of bone regeneration (Giuliani et al., 2016).
Somatic Stem Cells with Scaffolds in Dental Repair
and Regeneration
Stem cells and scaffolds could be transferred to dental canal
systems to help regenerate vital pulp and continue root formation
(Chrepa et al., 2015). Yadlapati et al. showed that VEGF-
loaded fiber was biocompatible and might be a promising
scaffold for additional optimization and use in endodontic
regenerative procedures (Yadlapati et al., 2017). Theocharidou
et al. proved low-level laser irradiation treatment to be beneficial
for odontogenic differentiation and biomineralization of DPSCs
inside the bioceramic scaffolds, making this therapeutic modality
promising for targeted dentin engineering (Theocharidou et al.,
2016). DPSCs and treated dentine matrix scaffolds were found to
associate with significantly more bone formation when used to
repair uninfected furcation perforations in the premolar teeth of
dogs (Bakhtiar et al., 2016).
There are 12 cases using scaffolds for stem cell therapy
among total 44 clinical trials correlated with oral disease
and oral stem cells (Tables 3, 4). Eight of them are for the
treatment of bone diseases including craniofacial abnormality,
mandibular fractures, bone atrophy, cleft palate, maxillary cyst,
and edentulous alveolar bone loss (five ongoing trials plus
three trials with reported results) and three for periodontal
diseases (NCT02449005, NCT00221130, NCT01082822), plus
one for in vitro regeneration of dental pulp-like tissue
with various scaffold and oral mucosa obtained during
surgical tooth extractions (NCT00595595). Bio-Oss scaffolds
were transplanted together with PDLS cell sheets for the
chronic periodontitis therapy in a completed clinical trial
(NCT01082822). Commercially available collagen scaffolds
(collagen fleece) are used to hold autologous BM-MSCs
enriched with autologous fibrin glue in clean room facilities
for regeneration of periodontal tissues in periodontal infrabony
defects in an ongoing clinical trial (NCT02449005). For adult
periodontitis patients, the surgical implantation of autologous
MSCs with a 3D woven-fabric composite scaffold and platelet-
rich plasma showed no clinical safety problems but decreasing
trend of mobility and significantly improved changes in
clinical attachment level, pocket depth, and linear bone growth
(NCT00221130; Baba and Yamada, 2016).
Somatic Stem Cells with Scaffolds in Maxillofacial
Repair and Regeneration
Stem cells combined with scaffold could regenerate bones
effectively (Kitamura et al., 2011; Windisch et al., 2012). And
plastic compression of collagen scaffolds seeded with DPSCs was
shown to enhance the osteogenic differentiation of DPSCs as
it increased the collagen fibrillary density in a rat critical-size
calvarial defect model (Chamieh et al., 2016). In a clinical trial
(NCT00001391) to examine the potential of cultured human
bone marrow stromal cells which will ultimately be used to
graft into craniofacial osseous defects, prolonged bone formation
by transplanted bone marrow stromal cells was observed in
mouse models and consistent bone formation by human marrow
stromal fibroblasts was achieved within vehicles containing
hydroxyapatite/tricalcium phosphate ceramics (HA/TCP) in the
form of blocks, powder, and HA/TCP powder-type I bovine
fibrillar collagen strips (Krebsbach et al., 1997). Another clinical
trial (UMIN000006720) evaluated the use of tissue engineered
bone made of scaffolds and autogenous MSCs for maxillary sinus
floor augmentation or onlay plasty with simultaneous implant
placement in six patients with 3–5mm alveolar crestal bone
height. Results showed a mean increase in mineralized tissue
height of 7.3 ± 4.6mm postsurgically, indicating that injectable
tissue-engineered bone provided stable and predictable implant
success (Ueda et al., 2005). A clinical study demonstrated that
a DPSC/collagen sponge biocomplex could completely restore
human mandible bone defects and indicated that this cell
population could be used for the repair and/or regeneration of
tissues and organs (d’Aquino et al., 2009a). It is reported that
3 years after transplants in human mandibles, histological, and
in-line holo-tomography revealed that stem cells regenerated a
compact rather than a spongy bone. It created steadiermandibles,
which might well-increase implant stability and resistance to
mechanical, physical, chemical, and pharmacological agents
(Giuliani et al., 2013). MSCs from deciduous dental pulp
associated with a collagen and hydroxyapatite biomaterial
(Geistlich Bio-Oss R©) were used to reconstruct the alveolar bone
defect in cleft lip and palate patients, and the results showed
progressive alveolar bone union in all patients, final completion
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of the alveolar defect with an 89.5% mean bone height 6 months
postoperatively (NCT01932164).
The other five clinical trials using scaffolds for stem cells
are ongoing without reported results. An ongoing clinical trial
(NCT01389661) uses a bioengineered product composed of
mesenchymal stem cells and a patented cross-linked matrix of
autologous plasma for bone maxillary cysts refilling. Platelet rich
fibrin (PRF) and bone allograft (FDBA; SureOss, Hansbiomed,
Korea) are used to load the buccal fat pad derived stem
cells for the treatment of alveolar bone loss in maxillary
sinus augmentation (NCT02745379) and in posterior mandible
augmentation (NCT02745366). Tissue engineered construction
based on a synthetic tricalcium phosphate and autologous MSCs
obtained from oral mucosa is used for maxilla alveolar process
reconstruction in patients with verified diagnosis partially
edentulous maxilla and alveolar bone atrophy (NCT02209311).
Similarly, MSCs obtained from bone marrow are mixed
with bicalcium phosphate to augment the alveolar ridge
(NCT02751125).
Somatic Stem Cells without scaffolds in
Oral and Maxillofacial Regeneration
Stem cells are applied without scaffolds in most clinical trials
(32/44 of total trials; Tables 3, 4). There are 5 clinical trials
with reported results, 6 clinical trials completed without reported
results, and 21 trials ongoing without results. Among the
clinical trials with results, the MSCs, PDLSCs, and ADSCs are
used.
Oral MSCs have been used to promote the dental pulp
and periodontal tissue regeneration. In an ongoing pilot study
to determine whether MSC injections directly into mucosal
lesions in patients with oral cGVHD are able to alleviate the
symptoms and facilitate the reparative process, it states that
55% aGVHD patients who failed front-line steroid treatment
responded to MSC infusion in the finished phase II clinical
trial (NCT02055625). Intravenously infused allogeneic MSCs
suppressed autoimmunity by directing T cells toward Treg and
Th2, while suppressing Th17 and Tfh responses, and restored
salivary gland secretory function in both mouse models and
Sjögren’s Syndrome patients who have been resistant to multiple
standard treatments (NCT00953485). The study suggests that
allogeneic MSC treatment may provide an effective therapy for
Sjögren’s Syndrome patients (Xu et al., 2012). Although results
are not available yet, the other three trials with MSCs focused
on osseointegration (NCT02731586), and regeneration of bones
(NCT02755922, UMIN000011286).
Human PDLSCs, as well as DPSCs, SHEDs, and bone marrow
stem cells have been studied to regenerate periodontal tissues
(Seo et al., 2004; Ding et al., 2010; Khorsand et al., 2013;
Du et al., 2014; Fu et al., 2014). Clinical trial (NCT01357785)
identified no clinical safety problems that could be attributed
to the investigational PDLSCs and found a significant increase
in the alveolar bone height (decrease in the bone-defect
depth) in each group but no statistically significant differences
between the PDLSC group and the control group (Chen
et al., 2016). Another clinical trial showed reduction of pocket
probing depth and clinical attachment gain, while greater
linear bone gain at PDLSC sheets/β-TCP treated sites with
no adverse reaction in the finished four cases of autologous
transplantation of PDLSC sheets to the denuded root surface
during the modified Widman flap procedure for the treatment of
periodontitis (UMIN000005027, https://www.researchgate.net/
publication/266802767). Allogeneic human DPSCs are injected
in local infected periodontal tissue for the treatment of
chronic periodontal disease (NCT02523651) and a clinical trial
UMIN000002050 aims to establish human dental pulp stem cell
bank for dental diseases that extraction of tooth is necessary for
treatment. A clinical trial is ongoing to clarify the efficiency of
autologous SHED to regenerate pulp and periodontal tissue in
the patients with immature permanent teeth and pulp necrosis
(NCT01814436).
ADSCs represent an attractive and ethical cell source for stem
cell therapy and have been used in six clinical trials (Table 3).
Intramuscular autologous transplantation of ADSCs enhance the
survival of fat grafted into the face in patient with progressive
hemifacial atrophy (NCT01309061), suggesting ADSC injection
may be used to treat Parry-Romberg disease without the need
for microvascular free flap transfer (Koh et al., 2012). The three
ongoing clinical trials of ADSCs without scaffolds aim to treat
periodontitis, radiation induced xerostomia, and cranial nerve
dysfunction.
APPLICATION OF ORAL DERIVED STEM
CELLS IN NON-ORAL DISEASES
Oral derived multipotent mesenchymal stem cells are able
to differentiate into odontoblast, cementoblast, osteoblast,
chondrocyte, adipocyte, melanocyte, endothelial cell hepatocyte,
and even myoblast and neural cell. Hence, besides the area
of oral diseases, oral derived stem cells have the potential to
be applied in brain, eye, heart, liver, bone, skin, and muscle
diseases as well (Liu et al., 2015). In terms of animal models,
researcher from Japan (Mita et al., 2015) reported that intranasal
administration of SHED in a mouse model of Alzheimer’s
disease (AD) could result in substantially improved cognitive
function. The conditioned medium of SHED containing the
factors involved in multiple neuro-regenerative mechanisms
might account for the results. Iran scientists also showed that
improvement of behavioral symptoms was efficiently observed
in the mouse model of local sciatic demyelination damage
by lysolecithin after transplantation of the DPSCs, to which
a tetracycline (Tet)-inducible system expressing OLIG2 gene
had been transfected (Askari et al., 2015). And Maraldi et al.
confirmed strong potential of bioengineered constructs of stem
cell (including dental pulp derived stem cell)-collagen scaffold for
correcting large cranial defects in a rat model and highlighting
the role of stem cells in neovascularization during skeletal
defect reconstruction (Maraldi et al., 2013). Factors secreted
from dental pulp stem cells also showed multifaceted benefits
for treating experimental rheumatoid arthritis in animal models
(Ishikawa et al., 2016). As it was significantly effective both in
animal models. Evidence has been proved to be sufficient to step
Frontiers in Physiology | www.frontiersin.org 9 April 2017 | Volume 8 | Article 197
Yang et al. Stem Cell Therapy in Oral Diseases
forward from preclinical animal models to human studies in
regenerative medicine using oral-derived stem cells. Clinicians
and researchers from Japan, Mainland China, Taiwa, South
Korea, and France have all carried out clinical trials in eye
diseases (Table 4). Oral mucosal epithelial cell sheet was used
as the source of stem cells, and they were applied to treat
keratoconjunctival disease, corneal epithelial stem cell deficiency,
and limbal stem cell deficiency. As most of the trials are under the
condition of recruiting, no results are posted online.
APPLICATION OF IPS CELLS IN
DENTISTRY
iPS Cell Generation from Fibroblasts with
Four Defined Factors
For the application of iPS cells in disease treatment, the first step
is to get iPS cells with defined factors. Four factors Oct4, Sox2,
Nanog, and Lin28 are sufficient to induce pluripotent stem cells
from neonate fibroblasts (Yu et al., 2007). Masato and colleagues
found that some family proteins of the four factors Oct3/4, Sox2,
Klf4, and c-Myc are capable to reprogram mouse embryonic
fibroblasts (MEFs) to iPS cells, and they also found that iPS cells
can be generated withoutMyc although the generation of iPS cells
takes more time than with Myc (Nakagawa et al., 2008). More
than that, it has been shown that iPS cells can be induced from
primary human fibroblasts with Oct4 and Sox2 or be acquired
from mouse neural stem cells by introducing only one factor,
Oct3/4 (Huangfu et al., 2008; Kim et al., 2009). Nevertheless,
the four factors play important roles in the reprogramming, but
unique factors may be needed for different cell type.
Generation of Dental Stem Cells with iPS
Cell Technology
Four factors Oct4, Sox2, Nanog, and Lin28 or Oct3/4, Sox2,
Klf4, and c-Myc carried by viral vectors can reprogram three
different dental stem cells: SHED, SCAP, and DPSCs (Yan et al.,
2010). It has also been demonstrated that three factors without
c-Myc can reprogram adult wild-type mouse gingival fibroblasts
(GFs), but generation of iPS cells from primary human gingival
fibroblasts need four factors (Egusa et al., 2010;Wada et al., 2011).
In dentistry, researchers prefer to adopt the classical Yamanaka
iPS cell method. But dental tissues are very different from
fibroblasts, and there may be new transcription factors involved
in the induction. It was shown that miRNA-720 expressed in
DPSCs participates in the regulation of the pluripotency factor
Nanog and was involved in reprogramming (Hara et al., 2013;
Eguchi and Kuboki, 2016). MSC-like populations are rich in
dental tissues, which suggest that dental tissues have great
potential to be directly reprogrammed into other tissues using
defined transcription factors cultured in specific condition. More
studies are needed to optimize iPS cell method for dental tissue
reprogramming.
Dental Tissue Regeneration with iPS Cells
Many endeavors have been made with iPS cells to produce new
cementum, alveolar bone, ameloblast, and so on (Figure 3; Duan
et al., 2011; Yoshida et al., 2015). More and more researchers are
interested in the possibility of tooth regeneration from iPS cells.
The first trial to generate tooth-like structure from iPS derived
neural crest like cells was failed (Otsu et al., 2012). Shortly, tooth-
like structures, with bone-like and dental pulp-like areas, were
generated from mouse iPS cells by mixing iPS cells with both
embryonic dental epithelial and mesenchymal cells (Wen et al.,
2012). Furthermore, it was shown that tooth-like structures, of
which chemical composition are similar with human teeth, can
be generated from patient’s own urine induced pluripotent stem
cells (Cai et al., 2013). But generation of whole teeth from iPS
cells is still a challenge (Wen et al., 2012). The formation of
a tooth germ need the interaction between ectoderm-derived
epithelial cells and neural-crest-derived mesenchymal cells, so
iPS cells are supposed to differentiate into two lineages, and
one of them must be odontogenic (Ning et al., 2010). However,
it was showed that ES cell or iPS cell derived dental epithelial
cells did not have odontogenic potential (Arakaki et al., 2012).
Although, mouse iPS cells have potential to differentiate into
odontogenic mesenchymal cells through neural crest-like cells,
but no signal of tooth generation was shown (Otsu et al.,
2012). More work should be done to regenerate a whole
tooth.
Challenges for the Application of iPS Cells
in Dentistry
Using retroviruses to generate iPS cells is simple and
reproducible, and is the first choice in vitro studies. Integrating
viruses such as retroviruses or lentiviruses to deliver transcription
factors may cause insertional mutagenesis and induce
tumorigenesis. New techniques including transduction of
plasmids, proteins, and episomal expression vectors which
will disappear during culture are emerging (Okita et al., 2008;
Eggenschwiler and Cantz, 2009; Yu et al., 2009; Zhou et al.,
2009). However, virus-free methods are far less effective. In
dentistry, retroviruses and plasmids are favored methods. For
clinical application, integration-free methods are essential and
more effective integration-free methods are needed.
It was shown that 30% for eight different human iPS cell lines
differentiated into tooth-like structures successfully, although it
was less efficient compared with 100% differentiation efficiency
of mouse embryonic dental epithelium and dental mesenchyme
(Cai et al., 2013). It has been questioned always that the iPS
cells showed poorer differentiation capacity than ESCs. Neural
differentiation of human iPS cells showed lower efficiency than
ESCs (Hu et al., 2010) while other groups demonstrated that the
ability of human iPS cells to differentiate into motor neurons
has no difference with ESCs (Boulting et al., 2011). Although
there must be inherent differences among ESCs, MSCs, and iPS
cells, culture condition including types of feeder cells, medium,
etc. are equally important to successful differentiation. All the
conditions should be taken into account to optimizemethod. Ten
years of iPS cell studies are full of surprises and challenges. Tooth
regeneration was considered to be an important test ground
for application of iPS cells and will meet new surprises and
challenges.
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PERSPECTIVES
There are more than 6,000 clinical trials correlated with stem
cells but only total 44 registered clinical trials correlated with
oral disease and oral stem cells worldwide (Figure 4, Tables 3,
4, more details could be found in Supplementary Table 1).
Most of them are not completed and thus do not provide
results. Homogeneity of stem cells, their delivery methods, the
quality of regenerated tissues and whether it could be integrated
with the host are still the problems to be solved (Mitsiadis
et al., 2015). There are two main obstacles in stem cell therapy
especially in tissue repair and regeneration. One is how to get
enough desirable stem cells, the other is how to direct the
differentiation of stem cells into functional cells and tissues.
To get enough desirable adult stem cells, accurate cell surface
markers should be screened or identified and then they could
be used for isolation and enrichment of the stem cells. The
next important step is to set up an optimized condition that
the isolated stem cells could proliferate and expand to required
amount but not differentiate into any other cells. For iPS cells, it
is a key step to set up conditions to induce desirable pluripotent
cells. To achieve these goals, stem cell fate should be under
control.
Epigenetic Modification or Interference Is
the Main Strategy to Control Stem Cell Fate
Epigenetic modifications including modification of histone,
DNA methylation, and regulation of micro RNAs are established
to affect the maintenance and differentiation of stem cells.
DNA methylation and histone modifications are two primary
mechanisms to regulate transcriptions of genes in adult
stem cells. Generally, DNA methylation of CpG is associated
with transcriptional repression, while DNA demethylation
activate gene transcription. The modifications of post-
translational histone including methylation and acetylation
are major epigenetic regulation in dental pulp stem cells. The
functions of miRNAs in epigenetic regulation of stem cells
are extensively studied recently. Regulation of miRNA mainly
rely on translational inhibition by degradation of targeted
mRNA. Several miRNAs such as miRNA-204/211, miR-138,
miR-125b, and miR-21 are important regulators involved in
the osteogenic or adipogenic differentiation of bone marrow
stem cells (BMSCs; Eskildsen et al., 2011; Lu et al., 2013;
Hu et al., 2014; Wu et al., 2015). miR-720 was observed to
promote odontogenic differentiation in dental pulp stem cells
(Hara et al., 2013). Alteration of epigenetic modifications by
inhibitors can affect the reprogramming of somatic cells or stem
cells fate. It has been demonstrated that inhibition of DNA
methyltransferase can increase the reprogramming efficiency
of somatic cells dramatically (He et al., 2010). The balance
between acetylation and deacetylation can be altered by histone
deacetylases inhibitors (HDACi). HDACi including trichostatin
A (TSA) and valproic acid VPA can promote proliferation and
odontoblast differentiation of hDPSCs (Jin et al., 2013; Paino
et al., 2014; Duncan et al., 2016).
Growing evidence shows that epigenetic modifications play a
crucial role in the induction of iPS cell. As well as four defined
factors, reprogramming of histone modifications are required
for iPS cell induction. The situation of histone modification in
iPS cells and ESCs in pluripotency associated genes are in the
same, but in contrast to the differentiated cells. However, the
epigenetic reprogramming in iPS cells is not complete since
numerous differences in DNA methylation between human
ESCs and iPS cells were observed (Lister et al., 2011). These
differences are generated by reprogramming as well as epigenetic
memories from origin tissues, and will affect the differentiation
and application of iPS cells (Kim et al., 2010). For few knowledge
FIGURE 4 | Clinical trials correlated with oral stem cell and oral diseases in different regions. The numbers represent the number of clinical trials
(oral-related/total stem cell). The “oral-related” cases were generated as same as Table 3. The numbers of “total stem cell” are the summary of the cases obtained by
searching “stem cell” on clinicaltrials.gov and umin.ac.jp. Regional division was according to that on clinicaltrials.gov.
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about the epigenetic differences between iPS cells and ESCs,
complete reprogramming can’t be achieved now. Further efforts
should be drawn to this field.
The Combination of 3D Printing,
Nanotechnology, and Biomedicine Is the
Main State of the Art Technology to
Precisely Direct Stem Cell Differentiation
In vivo
Because of the progresses made recently, it is expected to be
no problem to get enough desirable stem cells in near future.
The most challenging issue is how to precisely control the
differentiation of adult stem cells and iPS cells in vitro and
in vivo. To address the issues, the researches could focus on
three directions. One is uncovering the differentiation pathways
of stem cells to a specific cell type. This step is most important
and difficult. The second is to precisely drive the differentiation
of stem cells in vitro with the target molecules, cytokines, or
transcription factors identified in the clarified differentiation
pathways. This step can also check or update the previous
findings. The last one is controlling stem cells to develop
accurately in vivo. This step, unlike the in vitro differentiation,
is very complicated due to the body responses and undefined
micro-environment. One ignored issue in wound repair and
organ regeneration with stem cells is that the stem cells may
migrate from the target area to elsewhere, thus reducing the
therapy efficiency. Moreover, the cytokines or differentiating
factors used to control stem cell fate will distribute everywhere in
the body, which exaggerate the difficulty of precisely direct stem
cell differentiation. The 3D print technology and nanotechnology
may help solve these issues.
Nanotechnology is defined as the manipulation of matter
with at least one dimension sized from 1 to 100 nanometers.
Nanomaterials have unique optical, electronic, or mechanical
properties and thus show special bioeffects. In a recent study
with DPSCs, the ROS-scavenging events of cerium nanomaterials
(CeNMs) were related to the aspect ratio-dependent cellular
internalization, suggesting the promising use of CeNMs to
protect stem cells from the ROS-insult environments and
ultimately improve the stem cell potential for tissue engineering
and regenerative medicine (Mahapatra et al., 2017). In another
study, it is reported that enhanced rapid bone regeneration
and complete mature bone-structure formation was obtained
when using the physiological electric potential and the fabricated
nanocomposite membrane mimicking the endogenous electric
potential (Zhang et al., 2016). It provides another strategy to
compose novel scaffolds for dental stem cells. And Heo et al.
found that gold nanoparticles (GNPs) coated titanium could
enhance the osteogenic differentiation in human adipose-derived
stem cells (Heo et al., 2016). What’s more, nano-thin polymeric
shells constructed and modified by nanostructure involvement
were used to immobilize the DPSCs with a layer-by-layer
technique to ensure the layers stability and integrity as well as
separation from bacterial cells (Grzeczkowicz et al., 2015).
3D bioprinting, the combination of 3D printing technology,
biology, and materials science, is the process of direct printing
of biological materials (cells, proteins, etc.) into a confined
space, where biological function and viability of biomaterials
are preserved within the printed construct (Murphy and Atala,
FIGURE 5 | Strategies for oral disease treatment with stem cells. Oral stem cells are sorted out and expanded in vitro and then (A) co-cultured with or seeded
in a 3D-printed scaffold made of nanomaterials in medium with growth factors for hours or days to form an organ-like structure, or (B) mixed with biomaterials, helper
cells, and growth factors to make bioink for bioprinters to print an organ-like structure which is immediately used for repair and reconstruction of impaired bones.
Together with helper cells and growth factors, stem cells can also be linked to nanomaterials (here showing magnetic nanoparticles) to form an immobilized format
(changed from free moving format) which can be loaded/seeded in either (C) the scaffold which will be implanted to impaired region, or (D) directly in the impaired
region. Magnetic field will prevent the migration of cells and growth factors/cytokines, and thus form a relative steady microenvironment which could direct stem cell
differentiation. (E) In situ stem cells around the impaired region could also be attracted and/or stimulated for controlled differentiation in the artificial microenvironment
which is established with magnetic immobilized helper cells, bioactive factors, gene regulation molecules, and chemicals.
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TABLE 5 | Pros and cons of stem cells with different origins in clinical application.
Autologous stem cells Allogeneic stem cells iPS cells References
Pros Hypoimmunogenic or
non-immunogenic; some of them
display immunomodulatory; derived
from accessible tissues such as
human exfoliated deciduous teeth
Derived from healthy tissues; with
numerous clinical studies; an established
treatment strategy for many malignant
hematological diseases
Pluripotency; non-immunogenic;
unlimited source; no ethical issues;
Girlovanu et al., 2015; Juric
et al., 2016
Cons Limited differentiation potential and
finite life span; limited sources; difficult
to treat the disease resulted from
gene mutations
Ethical problems; limited sources (lack of
suitable donor organs and tissues);
immune rejection
Differentiation potential limited by
epigenetic memory; tumorigenesis
Consentius et al., 2015;
Girlovanu et al., 2015
2014). One of the three major concepts in 3D bioprinting is
the type of bio-ink, which is made up of poly (ethylene glycol;
Arcaute et al., 2006; Chan et al., 2010), fibrinogen (Cui and
Boland, 2009; Lee et al., 2009) and/or alginate (Fedorovich
et al., 2012; Hockaday et al., 2012) and helped to maintain
both the biological function and viability of biomaterials and
the dimensions of printed objects (Shafiee and Atala, 2016). The
combination of nanotechnology and 3D printing technology,
allows the creation of sophisticated materials with exquisite
fine structural detail and provides fantastic therapy strategies.
Figure 5 outlines the strategies used potentially in oral disease
treatment. For example, bone stem cells can be administrated
in a 3D printed biocompatible and biodegradable scaffold which
is made of nanomaterials and matches the bone wound. Stem
cells, cytokines and cytokine expressing plasmids can be either
used as bioink to directly print an organ-like structure with
a bioprinter or loaded on magnetic nanoparticles (Sun et al.,
2011) and then precisely immobilized in the target area with
magnetic field. The design of novel nanostructured materials,
such as biomimetic matrices and scaffolds for controlling
cell fate and differentiation, and nanoparticles for diagnostics,
imaging and targeted treatment, is a novel direction for
stem cell therapy. The administration to patients of dynamic
biological agents comprising stem cells, bioactive scaffolds and/or
nanoparticles will certainly increase the regenerative impact of
dental pathological tissues (Mitsiadis et al., 2012).
Biosafety and the Development of
Technology Determine which Kind of Stem
Cells to Be Used for Oral Disease
Treatment
In summary, there are endogenous/autologous and
exogenous/allogeneic adult stem cells and iPS cells for oral
disease treatment. As compared in Table 5, these cells have
their own pros and cons features. The features suggest the
main research direction of stem cell therapy. For autologous/
endogenous stem cells, there are two main research directions:
try to expand the stem cells in vitro without stemness loss
or function change; try to speed up self-renewal of the in
situ stem cells and precisely control their differentiation. For
allogeneic stem cells, the in vitro expand technology is also
very important and the technology to lower down the immune
rejection is urgently needed. Besides the immune suppression
drugs, regulatory immune cells such as Treg and Breg (Sun et al.,
2015; Xu et al., 2016) may be used to overcome the immune
rejection and enhance the efficiency of stem cell therapy. For iPS
cells, the biosafety is the main issue that should be addressed
due to their high tumorigenesis. The advances of technologies
in these directions determine which stem cells could easily
reach a desirable number and show highest biosafety and
lowest immunogenicity, and therefore would be clinically used
successfully.
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